[
  {
    "ts": null,
    "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
    "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768325700,
      "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
      "id": 138087373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d"
    }
  },
  {
    "ts": null,
    "headline": "Merck Lifts Long-Term Revenue Target",
    "summary": "New drugs seen driving $70 billion by 2035",
    "url": "https://finnhub.io/api/news?id=ded3c036179fe537b19478b924792ea372265183c3edaf2071480a304eac2bb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768325692,
      "headline": "Merck Lifts Long-Term Revenue Target",
      "id": 138086726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "New drugs seen driving $70 billion by 2035",
      "url": "https://finnhub.io/api/news?id=ded3c036179fe537b19478b924792ea372265183c3edaf2071480a304eac2bb4"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=2b7695e2beedfa3ea8c953ed19767036b271ccd1aaba133d4bb2087f5d213804",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768305180,
      "headline": "Health Care Roundup: Market Talk",
      "id": 138083149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=2b7695e2beedfa3ea8c953ed19767036b271ccd1aaba133d4bb2087f5d213804"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target",
    "summary": "Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.",
    "url": "https://finnhub.io/api/news?id=49424a515a66b66db2e1e95fc1496a424f7841a4a1af23c4f4b25a425fd805eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768322700,
      "headline": "JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target",
      "id": 138091493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.",
      "url": "https://finnhub.io/api/news?id=49424a515a66b66db2e1e95fc1496a424f7841a4a1af23c4f4b25a425fd805eb"
    }
  },
  {
    "ts": null,
    "headline": "Merck KGaA Touts “Next Wave of Growth” at JPM Healthcare, Reaffirms 2025 Guidance, Eyes 2026 Upside",
    "summary": "Merck KGaA (ETR:MRK) Chief Executive Officer Belén Garijo used the company’s presentation at the 44th J.P. Morgan Healthcare Conference to outline what she described as a “next wave of growth,” anchored by three strategic growth pillars: Process Solutions in Life Science, rare diseases in Healthcare",
    "url": "https://finnhub.io/api/news?id=2f0b08b5fad118ef05f27358b2357775a402161ff34f3040f55fb2abce48a7fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768319334,
      "headline": "Merck KGaA Touts “Next Wave of Growth” at JPM Healthcare, Reaffirms 2025 Guidance, Eyes 2026 Upside",
      "id": 138086728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck KGaA (ETR:MRK) Chief Executive Officer Belén Garijo used the company’s presentation at the 44th J.P. Morgan Healthcare Conference to outline what she described as a “next wave of growth,” anchored by three strategic growth pillars: Process Solutions in Life Science, rare diseases in Healthcare",
      "url": "https://finnhub.io/api/news?id=2f0b08b5fad118ef05f27358b2357775a402161ff34f3040f55fb2abce48a7fc"
    }
  },
  {
    "ts": null,
    "headline": "Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery",
    "summary": "Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.",
    "url": "https://finnhub.io/api/news?id=f416e6c51aa734dff349ee105f949067ae902e1dc86ef8977b34801345333145",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768313700,
      "headline": "Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery",
      "id": 138084482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.",
      "url": "https://finnhub.io/api/news?id=f416e6c51aa734dff349ee105f949067ae902e1dc86ef8977b34801345333145"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
    "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
    "url": "https://finnhub.io/api/news?id=deaeebebd40a90e35b35a7807231ba998ff3cd4cb2bcc9a1b6aac5bf5c585504",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768311780,
      "headline": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
      "id": 138086668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
      "url": "https://finnhub.io/api/news?id=deaeebebd40a90e35b35a7807231ba998ff3cd4cb2bcc9a1b6aac5bf5c585504"
    }
  },
  {
    "ts": null,
    "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
    "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
    "url": "https://finnhub.io/api/news?id=4bbd2e0d05be89da16efff4aa039eb3fbef25f9109658ddf301a26ce3cc78431",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308840,
      "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
      "id": 138084496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
      "url": "https://finnhub.io/api/news?id=4bbd2e0d05be89da16efff4aa039eb3fbef25f9109658ddf301a26ce3cc78431"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
    "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
    "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308508,
      "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
      "id": 138083148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
      "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768299840,
      "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
      "id": 138083151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
      "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story",
    "summary": "Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.",
    "url": "https://finnhub.io/api/news?id=1e2a0d0945b504cee9d854447f8df038cdc967e81d575ea22e4cc1698c72c07f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768292119,
      "headline": "Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story",
      "id": 138082884,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197456331/image_2197456331.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.",
      "url": "https://finnhub.io/api/news?id=1e2a0d0945b504cee9d854447f8df038cdc967e81d575ea22e4cc1698c72c07f"
    }
  }
]